Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Care management intervention strategies
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Care management intervention strategies

1 evidence topic · 1 source

Standardized screening and diagnostic testing

“Standardization of screening and diagnostic testing improves SM diagnosis and KIT p.D816V detection rates.” (opens the source at this quote in a new tab)